Children's Cancer Research Fund logo

Children's Cancer Research Fund

Families and Friends Who Care

research grants awarded

After 28 years of funding, CCRF has just awarded its 80th research grant! Since Children's Cancer Research Fund is not the arm of any one hospital, it is able to fund research on a national level.

2017

Nirali N. Shah, M.D.

Pediatric Oncology Branch, National Cancer Institute

Bethesda, MD

*A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia


Burke, Michael, M.D.

Medical College of Wisconsin

Milwaukee, Wisconsin

*Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML

2016

Burke, Michael, M.D.

Medical College of Wisconsin

Milwaukee, Wisconsin

*Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults with Relapsed/Refractory AML

2015

Rheingold, Susan R., M.D. (co-chair)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania


Silverman, Lewis B., M.D. (co-chair)

Dana Farber Cancer Institute

Boston, Massachusetts


*A Phase 1 Trial of Tremsirolimus in Combination with Etoposide and Cyclophosphamide in Children with Relpased Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

2014

Burke, Michael, M.D.

Medical College of Wisconsin

Milwaukee, Wisconsin

*A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL

2013

HEDGE, MEENAKSHI, M.D.

Baylor College of Medicine

Texas

*Adoptive immunotherapy co-targeting tumor cells and tumor endothelium in Glioblastoma

2012

PAREKH, CHINTAN, M.D.

Children's Hospital of Los Angeles

Los Angeles

*Micro-RNA-transcription factor networks in T-cell acute lymphoblastic Leukemia

2011

REDELL, MICHELE, M.D., Ph.D.

Texas Children's Cancer and Hematology Centers

Houston, Texas

*Identifying Chemotherapy Resistance Mechanisms in Relapsed Acute Myeloid Leukemia

SEPE, DANA, M.D.

Center for Childhood Cancer Research & Division of Oncology, The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania

*Pharmacokinetics in Pediatric Cancer Patients

DRISSI, RACHID, Ph.D.

Cincinnati Childrens Hospital Medical Center

Cincinnati, Ohio

*Biology Studies in the First Phase I Trial of a Telomerase Inhibitor in Children with Refractory of Recurrent Solid Tumors and Lyphomas

2010

BARBIERI, EVELINE, M.D., Ph.D.

Baylor College of Medicine

Houston, Texas

*Sestrins Modulate p53-Dependent Responses to Chemotherapy in Neuroblastoma.

KRIVTSOV, ANDREI, Ph.D.

Childrens Hospital Boston

Boston, Massachusetts

*Preclinical Assessment of Ctnnb1 Suppression for Treatment of MLL-AF9 AML/LSC.

ROY, UPAL BASU, Ph.D., M.P.H.

New York University Medical Center

New York, New York

*Targeting Sox2-positive Stem Cells in Osteosarcoma.

STAKE, NORIKO, M.D.

University of California, Davis

Sacramento, California

*Leukemia-Specific Ligands Against Childhood Acute Lymphoblastic Leukemia.

2009

ARA, TASNIM, M.D., Ph.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Role of IL-6/STAT-3 and AKT signaling in Neuroblastoma Chemoresistance and Tumor progression in Bone Marrow Microenvironment.

RAINUSSO, NINO, M.D.

Baylor College of Medicine

Houston, Texas

*Immunotherapy to Target Cancer Stem Cells in Pediatric Osteosarcoma.

SATWANI, PRAKASH, M.D.

Columbia University

New York, New York

*A Novel Chemotherapy (Romidepsin) and Immunotherapy (Natural Killer Cell) Based Approach in Pediatric Leukemia and Lymphomas: Potential for Targeted Adoptive Cellular Immunotherapy (ACI).

VROOMAN, LYNDA, M.D.

Dana-Farber Cancer Institute

Boston, Massachusetts

*Volumetric Bone Mineral Density Changes During and After Childhood Acute Lymphoblastic Leukemia Therapy.

2008

KESHELAVA, NINO, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Overcoming Neuroblastoma Drug Resistance with Histone Deacetylase Inhibitors and Flavopiridol.

MITTLEMAN, STEPHEN D., M.D., Ph.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Exploring How Obesity and Adipocytes Affect Childhood Cancer.

OKCU, MEHMET F., M.D., Ph.D.

Baylor College of Medicine, Texas Childrens Hospital

Houston, Texas

*Glutathione S-Transferase P1 Variation and Survival in Children with High Risk Neuroblastoma.

SONG, HAE-RI, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Nuclear Factor I A gene, and Astrocytic Lineage Gene, in Glioma Formation.

2007

ASGHARZADEH, SHAHAB, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Genomics of Metastatic Neuroblastomas Lacking MYCN Amplification.

GREGORY, MARK A., Ph.D.

University of Colorado Health Sciences Center

Aurora, Colorado

*Identifying Candidates for Targeted Therapy in Combination with FLT3 Inhibition for the Treatment of Acute Myeloid Leukemia.

WELLS, JAMES, M.D.

Bringham and Women's Hospital, Inc.

Boston, Massachusetts

*EWS-Flil as an Immuno-Therapeutic Target for Ewing's Sarcoma.

2006

ARMSTRONG, MICHAEL B., M.D., PH.D.

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan

*Impact of N-myc on Chemoresistance in Neuroblastoma.

HELLER, KEVIN N., M.D.

The Rockefeller University

New York, New York

*Epstein-Barr Virus Immunity and Lymphoma.

KEATING, AMY K., M.D.

UCHSC at Fitzsimmons, Pediatrics

Aurora, Colorado

*Mer Receptor Tyrosine Kinase as a Biological Marker and Therapeutic Target for Pediatric Leukemia.

RABIN, KAREN, M.D.

Texas Children's Cancer Center

Houston, Texas

*Acute Lymphoblastic Leukemia in Down Syndrome: An Investigation of Molecular Genetics and Host Toxicity.

2005

BARRY, ELLY FALZARANO, M.D.

Dana Farber Cancer Institute

Boston, Massachusetts

*Pharmacogenomics of Doxorubicin-induced Cardiotoxicity.

KEATES-BALEEIRO, JENNIFER, M.D.

Vanderbilt Children's Hospital

Nashville, Tennessee

*Testing Novel Therapeutics in a Mouse Model if Inv (16).

ZACHAROULIS, STERGIOS, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Preclinical Evaluation of VEGFR2/EGFR Inhibition in Combination with MetronomicTemozolomide in a Mouse Model of High Grade Gliomas.

2004

HAINING, W. NICHOLAS, B.M., B.CH.

Dana Farber Cancer Institute

Boston, Massachusetts

*Targeting telomerase as a cancer antigen: a phase 1 pediatric tumor vaccine trial.

KARAJANNIS, MATTHIAS, A., M.D.

Memorial Sloan-Kettering Cancer Center

New York, New York

*Role of pro-angiogenic factors in leukemia-stroma interactions.

ONEL, KENAN, M.D., PH.D.

The University of Chicago

Chicago, Illinois

*The Identification of Novel Biomarkers and Therapeutic Targets in Pediatric ALL by Correlative Analysis of Genome Copy Number Alterations, mRNA Expression, and Clinical Characteristics.

2003

ASGHARZADEH, SHAHAB, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Gene Expression Profiles of Metastic Neuroblastomas without MYCN Amplification Predict Outcome.

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.

Childrens Hospital Los Angeles

Los Angeles, California

*The antiangiogenic effect of alphav-integrin inhibition combined with fenretinide in mouse models of human brain tumors.

REID, GREGOR, M.D., PH.D.

BC Research Institute for Child and Family Health

Vancouver, British Columbia

*Development of immune therapy for ETV6-AML1 positive leukemia using a novel mouse model.

Children's Cancer Research Fund Research Grant Locations

2002

APLENE, RICHARD, M.D.

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania

*Genetic Polymnorphisms and Anthracycline Associated Cardiac Toxicity.

BROWN, VALERIE I., M.D., PH.D.

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania

*Evaluation of mTOR Inhibitors and the Role of IL-7 Signaling in Lymphoid Malignancies.

GRAHAM, DOUGLAS K., M.D., PH.D.

University of Colorado Cancer Center

Denver, Colorado

*Evaluation of role of proto-oncogene c-mer in acute lymphocytic leukemia.

PUNAM, MALIK, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*In Vivo Effects of Erythropoietin Receptor Signaling in Pediatric Tumors.

2001

BATRA, SANDEEP, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Activity of fenretinide (4-HPR) and 4-HPR plus safingol in preventing disease progression against pediatric Ewing's Sarcoma (ES) and Primitive neuroectodermal Tumors (PNET) cell lines In Vitro and In Vivo.

MALIK, PUNAM, M.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Role of Erythropoietin and Erythropoietin Receptor in Pediatric Tumors.

ROOD, BRIAN, M.D.

Children's National Medical Center

Washington, D.C.

*Methylation of the O6-methylguanine methyltransferase (MGMT) gene promoter as a prognostic factor in pediatric high grade glioma and medulloblastoma.

WEIGEL, BRENDA, M.D.

University of Minnesota Medical School

Minneapolis, Minnesota

*Combination Immunotherapy and Chemotherapy for Rhabdomyosarcoma.

2000

MAURER, BARRY J., M.D., PH.D.

Childrens Hospital Los Angeles

Los Angeles, California

*Novel Retinoid Combinations with Selective Cytotoxicity for Malignant Cells.

WANG, LISA L., M.D.

Baylor College of Medicine, Texas Children's Cancer Center

Houston, Texas

*Molecular Basis and Clinical Spectrum of Rothmund-Thomson Syndrome.

1999

SAVASAN, SUREYYA, M.D.

Wayne State University

Detroit, Michigan

*In Vitro Drug-Induced Apoptosis as a Measure of Chemo-sensitivity in Childhood T-Cell Acute Lymphoblastic Leukemia.

VAN TORNOUT, JAN M., M.D., M.S.

Childrens Hospital Los Angeles

Los Angeles, California

*Evidence for Gene - Environmental Interaction(s) in the Etiology of Pediatric Brain Cancer.

SWEETSER, DAVID A., M.D., PH.D.

Fred Hutchinson Cancer Research Center

Seattle, Washington

*The Significance of Loss of Heterozygosity in the Patho-genesis and Prognosis of Pediatric de novo AML.

1998

FU, CECILIA, M.D.

USC School of Medicine/Childrens Hospital Los Angeles

Los Angeles, California

*Evaluation of Apoptotic Oncoproteins in Blast Cells from Pediatric Patients with Leukemia at Diagnosis and at Relapse.

KESHELAVA, NINO, M.D.

USC School of Medicine/Childrens Hospital

Los Angeles, California

*Resistance to Alkylating Agents in Neuroblastoma.

1997

MALONEY, KELLY, M.D.

University of Colorado Health Sciences Center

Denver, Colorado

*Retrospective Analysis of Prognostic Import of TEL Rearrangements and Hyperdiploidy on Treatment Outcomes for Children with Standard Risks ALL treated with a Single Delayed Intensification.

SHOHET, JASON, M.D.

University of Texas Southwestern Medical Center

Dallas, Texas

*Analysis of Differentially Expressive Genes in Normal and Neoplastic B-Cells.

1996

ORCHARD, PAUL, M.D.

University of Minnesota

Minneapolis, Minnesota

*Expression of anti-CD 19 scFv/zeta Chimeric Gene in Human NK Cells.

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.

USC School of Medicine/Childrens Hospital Los Angeles

Los Angeles, California

*Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric Neural Tumors.

1995

ERDREICH-EPSTEIN, ANAT, M.D., PH.D.

USC School of Medicine/Childrens Hospital Los Angeles

Los Angeles, California

*Integrin Alpha-v Beta-3 in Angiogenic Signaling in Pediatric Neural Tumors.

TAUB, JEFFREY, M.D.

Children's Hospital of Michigan

Detroit, Michigan

*The Molecular Basis of Cytarabine Sensity of Down Syndrome Children.

1994

WEST, DANIEL C., M.D.

Dana-Farber Cancer Institute/Harvard Medical School

Boston, Massachusetts

*Testing the feasibility of using the PCR Technique to measure the presence of Ewing's Sarcoma or Peripheral Neuraoecto- dermal Tumors.

SCHMIDT, MARY LOU, M.D.

Northwestern University Children's Memorial Hospital

Chicago, Illinois

*The Biologic Effects of Down-regulation of N-myc Oncogene Expression in Human Neuroblastoma. (continued study)

1993

HAMRE, MERLIN R., M.D., M.P.H.

Children's Memorial Institute for Education and Research

Chicago, Illinois

*Mechanisms of Resistance to Nucleoside Analogue Inhibitors of S-Adenosyl-L-Homocysteine hydrolase in Murine and Human Neuroblastoma Tumor Cell Lines: Enzymatic and Genetic Determinants.

WHITLOCK, JAMES, A., M.D.

Vanderbilt University Medical Center

Nashville, Tennessee

*Acquired and Constitutional Alterations of p53 in the Devel- opment and Progression of Childhood Central Nervous System Tumors.

1992

EMANUEL, PETER D., M.D.

University of Alabama at Birmingham

Birmingham, Alabama

*Mechanisms of Response and Effectiveness of 13-Cis Retinoic Acid in the Treatment of Juvenile Chronic Myelogenous Leukemia.

TOMLINSON, GALE E., M.D., PH.D.

University of Texas Southwestern Medical Center

Dallas, Texas

*A Search for predisposition factors in Breats/Sarcoma Cancer Families.

SCHMIDT, MARY LOU, M.D.

Northwestern University Children's Memorial Hospital

Chicago, Illinois

*The Biologic Effects of Down-regulation of N-myc Oncogene Expression in Human Neuroblastoma.

SHANNON, KEVIN, M.D.

University of California, San Francisco

San Francisco, California

*Mutations of the Neurofibromatosis and Ras Genes in Childhood Myeloproliferative Syndromes.

1991

MOULTON, THOMAS, M.D.

Columbia University College of Physicians & Surgeons

New York, New York

*The Role of Classic Multidrug Resistance in Pediatric Solid Tumors.

RAUCK, AMANDA M., M.D.

Children's Hospital

Columbus, Ohio

*Urokinase and It's Receptor in Pediatric Cancers - the Tumor Biology of Wilms' Tumor and Neuroblastoma, Development and Metastasis.

UMIEL, TEHILA, PH.D.

Children's Hospital of Los Angeles

Los Angeles, California

*Isolation, Molecular Characterization and Induction of Differ- entiation of Mixed Lineage (Myeloid/Lymphoid) Precursors from Norman and Leukemic Human Bone Marrow.

SCHMIDT, MARY LOU, M.D.

Northwestern University Children's Memorial Hospital

Chicago, Illinois

*Inhibition of N-myc Gene Expression with Antisense N-myc RNA.

HUANG, CHIEN-SHENG, M.D.

University of California, San Diego

La Jolla, California

*Use of Ch14.18 and GM-CSF Neuroblastoma.

VAN TORNOUT, JAN M.A., M.D.

Children's Hospital of Los Angeles

Los Angeles, California

*The Use of Neural Networking in Pediatric Outcome of Childhood Cancer.

TOMLINSON, GAIL E., M.D., PH.D.

University of Texas Southwestern Medical Center

Dallas, Texas

*Constitutional p53 Mutations in Childhood Patients.

1990

SAYLORS, ROBERT L. III, M.D.

Washington University School of Medicine

St. Louis, Missouri

*C-myc Activation in Medulloblastoma.

SMITH, THOMAS J., M.D.

National Jewish Center for Immunology and Respiratory Medicine

Denver, Colorado

*Vbeta Specificity of T-cell Leukemia and other T-cell Lymphoproliferative Disorders.

VILLABLANCA, JUDITH, M.D.

Children's Hospital of Los Angeles

Los Angeles, California

*Significance of Cellular Proliferation in Neuroblastoma.

1989

WINICK, NAOMI J., M.D.

University of Texas Southwestern Medical Center

Dallas, Texas

*6-Mercaptopurine Metabolism in Children with Acute Lymphoblastic Leukemia.

GREFFE, BRIAN, M.D.

The Children's Hospital

Denver, Colorado

*Effect of L-Asparaginase on the regulatory coagulation proteins and vWF as a mechanism for thrombosis in children with leukemia and lymphoma.